According to TechSci Research report, “Global Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025”, Global human insulin market was valued at USD26.91 billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Rising incidences of Type 1 diabetes in developed as well as developing countries and increasing geriatric population to drive the global human insulin market through 2025. Advancing medical facilities, evolving healthcare infrastructure, and increasing disposable incomes are also expected to propel the global human insulin market in the coming years. With R&D rising in insulin therapeutics, many recent advancements have resulted in new product launches with high efficacy rates, adding to the already augmented demand for insulin. 

Browse 227 Figures spread through 311 Pages and an in-depth TOC on " Global Human Insulin Market"

https://www.techsciresearch.com/report/human-insulin-market/4637.html

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products and region. Based on indication, global human insulin market can be segregated into type I diabetes and type II diabetes. Type I diabetes is leading the market as all the patients suffering from Type I insulins are consuming human insulin as the primary method of treatment.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4637

Customers can also request for 10% free customization on this report.

Some of the leading players in global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A., Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer, Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., etc. In order to expand their market share, the companies adopt various strategies including organic and inorganic like mergers & acquisition. For instance, Eli Lilly and Boehringer Ingelheim GmbH, the two renowned biotech & pharma companies in the healthcare sector have joined hands to develop Basaglar (Insulin Glargine) for better and advanced treatment of diabetic patients.

“In terms of regional analysis, North America dominated the global human insulin market in 2019 due to increasing cases of diabetes in countries like United States and Canada. However, Asia-Pacific region is expected the fastest growing region as it comprises of countries like China and India which have high prediabetic and diabetic population. Additionally, rising awareness pertaining to the use of human insulin in diabetes and strong distribution network of leading product manufacturers is anticipated to positively impact the growth of the market in the region.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025”, has evaluated the future growth potential of global human insulin market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global human insulin market.

Browse Related Reports

Europe Biosimilar Insulin Glargine & Lispro Market By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024

https://www.techsciresearch.com/report/europe-biosimilar-insulin-glargine-and-lispro-market/4278.html

Asia Pacific Biosimilar Insulin Glargine & Lispro Market By End User (Type 1 Diabetes and Type 2 Diabetes), By Country (Japan, China, India, South Korea, Bangladesh, Pakistan), Competition, Forecast & Opportunities, 2024

https://www.techsciresearch.com/report/asia-pacific-biosimilar-insulin-glargine-and-lispro-market/4282.html

Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]